Actinium Pharmaceuticals (ATNM) investor relations material

Investment highlights and strategic positioning

• Differentiated radiotherapy pipeline targets solid tumors and hematologic malignancies, with key data readouts expected in 2026 and a cash runway into 2028.

• ATNM-400 and Actimab-A (MDSC) offer pan-cancer opportunities, including resensitizing immunotherapies and targeting prostate, lung, and breast cancers.

• Hematology and conditioning franchise is late-stage and partner-ready, addressing the full AML treatment journey and universal conditioning for cell & gene therapies.

• Robust R&D, expanding in-house manufacturing, and strong IP portfolio (~250 patents) support near-term catalysts.

• Clean capital structure with $36.5M cash, no debt, and 31.4M shares outstanding.

Radiopharma market landscape and innovation

• Six major pharma players dominate with undifferentiated radiotherapy assets, leaving a gap for novel programs.

• Over $17 billion in M&A has created underutilized manufacturing infrastructure and a need for innovative assets.

• Investments in differentiated platforms and novel targets are accelerating, with a focus on pan-cancer and mutation-agnostic therapies.

Pipeline overview and clinical development

• Three pillars: solid tumors (ATNM-400, Actimab-A MDSC), hematology (Actimab-A, lomab-B), and conditioning (lomab-ACT).

• ATNM-400 is preclinical, targeting mCRPC, NSCLC, and breast cancer; Actimab-A MDSC is in Phase 1 for solid tumors.

• Hematology programs are Phase 2/3-ready, with Actimab-A and lomab-B addressing AML and BMT conditioning.

• Conditioning franchise aims to unlock curative therapies and improve patient access.